Clinical Trials in Nashville

Showing 4761-4780 of 20,298 trials

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

NCT05357612

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Neurodegenerative DiseasesParkinson DiseaseParkinson Disease Psychosis

Vanderbilt University Medical Center75 participantsStarted Jan 2023

Nashville, Tennessee, United States

Active Not RecruitingPhase 2/3< 1 mile

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.

Diabetic Macular Edema (DME)

EyeBiotech Ltd.984 participantsStarted Aug 2024

Scottsdale, Arizona, United States • Fayetteville, Arkansas, United States • Springdale, Arkansas, United States +180 more locations

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Find Trials by Condition in Nashville

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Impact of a Prehospital Sepsis Protocol on Timely Antibiotic Administration and Subsequent Adverse Events

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies